Should Newer Oral Anticoagulants Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism? New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation

被引：54

作者：

Ansell, Jack ^{[1
]}

机构：

[1] Lenox Hill Hosp, Dept Med, New York, NY 10075 USA

来源：

CIRCULATION | 2012年 / 125卷 / 01期

关键词：

PROTHROMBIN COMPLEX CONCENTRATE; COST-EFFECTIVENESS; DIRECT THROMBIN; DABIGATRAN; WARFARIN; NONADHERENCE; SAFETY; ADHERENCE; REVERSAL; THERAPY;

D O I：

10.1161/CIRCULATIONAHA.111.031153

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：165 / 170

页数：6

共 46 条

[1]

Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran [J].

Agnelli, G. ;

Eriksson, E. L. ;

Cohen, A. T. ;

Bergqvist, D. ;

Dahl, O. E. ;

Lassen, M. R. ;

Mouret, P. ;

Rosencher, N. ;

Andersson, M. ;

Bylock, A. ;

Jensen, E. ;

Boberg, B. .

THROMBOSIS RESEARCH, 2009, 123 (03) :488-497

[2]

Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690

[3]

Albers GW, 2003, LANCET, V362, P1691

[4]

[Anonymous], 2010, PRAD

[5]

[Anonymous], FDA DRUG SAF COMM SP

[6]

Pharmacology and management of the vitamin K antagonists [J].

Ansell, Jack ;

Hirsh, Jack ;

Hylek, Elaine ;

Jacobson, Alan ;

Crowther, Mark ;

Palareti, Gualtiero .

CHEST, 2008, 133 (06) :160S-198S

[7]

Ansell Jack E, 2003, Semin Vasc Med, V3, P261

[8]

The Relative Cost-Effectiveness of Anticoagulants Obvious, Except for the Cost and the Effectiveness [J].

Avorn, Jerry .

CIRCULATION, 2011, 123 (22) :2519-2521

[9]

Campbell HA, 1941, J BIOL CHEM, V138, P21

[10]

OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].

CANNEGIETER, SC ;

ROSENDAAL, FR ;

WINTZEN, AR ;

VANDERMEER, FJM ;

VANDENBROUCKE, JP ;

BRIET, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17

← 1 2 3 4 5 →